Background. Misuse of prescription opioids, and other drugs prescribed for chronic pain, has increased, with major concerns about harm. This review was undertaken to identify validated measurement tools for risk assessment and monitoring of chronic non-cancer pain patients being considered for, or currently prescribed, analgesic drugs with abuse potential. Methods. Selected databases (Embase, Medline, Cochrane library/CENTRAL, PsycINFO, PubMed, CINAHL) were systematically searched for studies evaluating tools for risk of analgesic misuse, either before, or during, analgesic therapy for chronic pain, using predetermined inclusion/exclusion criteria. Two independent reviewers assessed abstracts, selected full texts, extracted data and assessed quality. Results. 30 studies from 1844 met inclusion criteria, including three systematic reviews, with an additional four studies from bibliography review. The studies covered 14 tools pertaining to opioid use, with none for non-opioid analgesics. Although there is no single, clear factor identifying opioid misuse, previous substance misuse appears important. Deception, including lying to clinicians, and using drugs belonging to others are common features. Smoking history may be relevant. Conclusions. For predicting prescription opioid misuse, the pain medication questionnaire (PMQ) and the screener and opioid assessment for patients with pain (SOAPP) had the best evidence; both developed and validated in five separate studies (four each of acceptable quality). The current opioid misuse measure (COMM) performed best screening for current misuse, developed and validated in three studies of acceptable quality. A small number of tools may accurately predict, or identify, opioid misuse. There are none for non-opioid analgesics, where there is a potential need.
several tools have been developed to assess this for opioids. These can be used in conjunction with clinical judgment and urine toxicology. Identified risks include patient characteristic factors such as younger age, more reported pain, genetic variables, and abnormal drug seeking behaviours. 15 Some studies of available tools have excluded those with past substance use, and have largely been tested in tertiary pain clinic settings, so may be less applicable to routine clinical practice. 16 A number of systematic reviews have been carried out to assess risk of opioid misuse, although there have been no reviews of other analgesic agents. [17] [18] [19] [20] [21] Misuse of gabapentin and pregabalin, also used for chronic pain, is a major new emerging problem, 22 and risk assessment for this is also becoming increasingly important. This review aimed to evaluate the use of validated measurement tools to assess risk of analgesic misuse (opioid and nonopioid), or associated aberrant drug-related behaviours, either before, or during, analgesic therapy for chronic pain. Although the search strategy included tools pertaining to tricyclic antidepressants and gabapentinoids and opioids, the only studies that were found examined risk of opioid misuse.
Methods
The review was registered with the PROSPERO international prospective register of systematic reviews (registration number 42016030087). 23 Selected databases (Embase, Medline, Cochrane library/ CENTRAL, PsycINFO, PubMed, CINAHL) were systematically searched for studies, using the following inclusion and exclusion criteria. Search strategies are shown in Supplementary Appendix S1.
Inclusion Criteria:
• Population: Adults (18 and over) with a diagnosis of chronic pain (pain persisting for more than three months), where analgesic medication is prescribed or under consideration • Type of studies: Systematic reviews of controlled trials and prospective observational studies; controlled trials comparing use of a validated assessment tool with no tool (or with another tool), or open label extensions; prospective observational studies evaluating the use of a validated assessment tool; studies using an accepted method of assessing misuse of prescribed analgesics (clinical interview, structured interview, questionnaires, prescription drug monitoring, drug screening).
Studies describing the initial derivation of tools and preliminary validation were also included • Outcome Measures: Prediction of prescribed analgesic misuse (defined as taking more than the quantity prescribed; more frequent requests for prescriptions; or taking analgesics when not required for pain relief)
• Yr: 1990 to December 2015 • Publication status: Published in a peer-reviewed journal Exclusion Criteria:
• Studies including patients with acute or cancer pain • Studies using tools to predict misuse of non-prescribed substances • Non-English language studies • Editorials, commentaries, narrative reviews, conference proceedings, meeting abstracts. Studies retrieved from searched terms were checked for duplicates, which were removed. Two independent reviewers (R.L. & D.M.) reviewed all the resulting abstracts to select eligible articles. Differences were discussed with an experienced third party (L.C.). Both reviewers then reviewed full copies of all eligible articles, and extracted data in accordance with pre-specified data items: The reviewers also assessed risk of bias for included studies using the Cochrane "Risk of Bias" criteria. 24 Each study was rated as being of high, acceptable or low quality using the methodology outlined in the relevant Scottish Intercollegiate Guidelines Network (SIGN) checklists. 25 Risk of bias across all studies was also considered, including publication and selective reporting bias. Any differences were resolved by discussion that included the experienced third party noted above.
Results
Searches of all databases yielded 1844 abstracts; 30 studies were selected for full text review, including three systematic reviews. Four additional studies were added for full review, after review of bibliographies.
No studies were identified that described or evaluated tools that screened for, or predicted, problematic use of either gabapentinoids or tricyclic antidepressants, so all pertained to tools designed to identify or predict possible problematic use of opioids. All studies described tools that were developed and validated in North America, although two included validation of tools in other European languages, but were published in English. Table 1 lists all included studies, with quality rating, and the tools evaluated, specifying both purpose and format, and grouped into five different categories according to what the authors state the tool measures. Where available, sensitivity, specificity, positive predictive value and negative predictive value are summarised in later tables. Study patient characteristics are included in Supplementary Appendix S2.
Tools predicting risk of aberrant drug related behaviours or prescription opioid misuse Seven tools were identified and reported by 17 studies, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] with results summarised in Table 2 . The STAR (screening tool for addiction risk) 26 was administered once to a population grouped by a recent history of substance abuse, with review of patient records at two months. The POTQ (physician opioid therapy questionnaire) 27 derived its questions from a review of addiction literature, incorporated into a psychological interview. The pain medication questionnaire (PMQ), developed in a study of acceptable quality, 28 has been more extensively tested. It is a 26-item tool, with statements that are rated on a 5-point Likert scale, and it was developed using literature regarding opioid misuse and clinician experience to evaluate the risk of aberrant drug related behaviours in patients prescribed opioids for chronic pain. The authors piloted it on a sample of 184 patients, all of whom were presenting for initial assessment at a pain clinic. Ninety-eight received interdisciplinary treatment, and 86 received medical treatment only. Just over 60% were prescribed opioids at the start of the study. Overall, PMQ scores were divided into thirds, with the highest scoring classified as H-PMQ and the lowest as L-PMG. Test-retest reliability was deemed adequate when the tool was re-administered to a subset of 19 patients after 30 min (Pearson's r coefficient 0.85). Internal consistency improved when four items were dropped (Cronbach's alpha coefficient increased from 0.73 to 0.75). This study used a number of tools to assess pain and personality, mood and mental health, and the physician risk assessment (PRA), which was developed specifically for the study to measure clinicians' evaluation of risk. Concurrent validity was tested using both the PRA and knowledge of opioid misuse, and there was a correlation between these two measures and higher PMQ scores, but numbers were small. Convergent validity was calculated for substance abuse potential, disability & psychosocial distress, and discriminant validity for well-being and psychosocial coping, and was found to be significant (P<0.01).
The PMQ was further validated in a prospective study of 271 new patients to a pain management programme. 29 This study was also of acceptable quality, and again compared high (H-PMQ), medium (M-PMQ) and low (L-PMQ) groups (across a normal distribution). Those in the H-PMQ group were 2.6 times more likely to have known substance abuse when compared with those in the L-PMQ group (95% CI 1.27-5.32). The physician risk assessment was completed, with significant differences between the high, and both the medium and low scoring groups (SDs given). There were also significant differences in mean PMQ scores of 60 patients who asked for early medication refills and those who did not. Only 39 subjects of the original 271 took the PMQ both before and after treatment, and these showed a significant reduction in scores after treatment. Patients in the high scoring group were also 2.3 times more likely to leave treatment because of a lack of compliance than those in the lowest scoring group (95% CI 1.03-5.02).
The PMQ was further validated in two other studies, both of acceptable quality. The first prospectively studied a sample of 388 new patients at a pain management centre, although only 249 completed the PMQ so were included. 30 There were no significant differences in patient characteristics and outcomes between those who completed and those who did not. They used the physician risk assessment (carried out without knowing the PMQ score), and a battery of questionnaires, and noted patient medication agreements and early prescription refills from patient charts. As in previous studies, they scored subjects into groups, but used only H-PMQ (25) One other study, considered of low quality, was an initial validation of a Danish version of the PMQ, but of the 209 subjects, 7% had pain as a result of malignant disease, so the study was of limited relevance to this review. 43 The authors screened for addiction using Portenoy's criteria, which had been validated by the first author in another study, for the purpose of identifying addiction in patients with chronic pain treated with opioids. These criteria include desire and compulsive use of a drug and aberrant behaviours, such as manipulation of health professionals to acquire drugs, obtaining drugs from other sources, hoarding of drugs, and use of other drugs or alcohol. 44 The authors used a discriminant function analysis based on a diagnosis of addiction using Portenoy's criteria to generate sensitivities and specificities for different cut-off scores of the PMQ, with a score of <22 giving a sensitivity of 82% and specificity of 58%. The screener and opioid assessment for patients with pain (SOAPP) Version 1.0 was developed in an acceptable quality study, 33 then further refined to the SOAPP-R (revised version) in another study of acceptable quality. 35 The initial study used concept mapping by 26 experts in pain or addiction, with 39 further professionals then sorting and rating items. Concept maps were generated, and items were based on these. A 24-item tool was reduced to 14 items that appeared to predict aberrant drug related behaviours. The tool was validated on a sample of 175 Prospective open-label, non-randomized, non-comparative, multi-centre observational study.
• SOAPP-R, as part of UP (universal precautions) approach.
To evaluate risk of aberrant drug-related behaviours in patients with chronic pain in primary care & monitor risk & ADRBs.
24-item self-report tool Low Webster and colleagues, 2005
Prospective observational cohort studydevelopment (derivation) and initial validation Prospective cross-sectional study.
• Development (derivation) and initial validation of toolprospective study
To monitor opioid adherence/compliance in chronic pain patients on long-term opioids
5-item self-report tool High
Jamison and colleagues, 2015
Prospective observational cohort study -further validation of OCC in primary care.
• Prospective observational study -to compare predictive validity of 3 tools.
• Development (derivation) and initial fieldtesting of tool.
• Pain Assessment and Documentation Tool (PADT)
Evaluate outcomes and record patient care
Clinician-directed interview. Brief 2-sided chart note. Revised version completed in min Acceptable Continued subjects, with six months follow up data collected for 95 out of 116. The aberrant drug behaviour index (ADBI), based on a structured interview (prescription drug use questionnaire -PDUQ), reports by clinical staff and urine toxicology, was used to validate the SOAPP. Internal consistency was reasonable (alpha coefficient 0.74), as was test-rest reliability after six months (Pearson product moment correlation 0.74). A score of 7 gave a sensitivity of 91% and specificity of 69%. The SOAPP-R was created using the original concept mapping from the SOAPP v.1.0, with a large number of items (142) used for an alpha version, of which 94 were retained for a beta version after empirical testing on 85 subjects. Twenty-four items were ultimately selected based on factors including content, consistency, reliability and effect size, and initial validation was carried out on 283 pain clinic patients. Sensitivities and specificities, positive and negative predictive values, and positive and negative likelihood ratios were calculated for different cut-off scores with a cut-off of 18 considered useful (shown in Table 3 ).
The SOAPP version 1.0 was further validated in a sample of 397 patients, of whom 159 were from a veteran's pain centre (98.1% of these were male, and 66% had a service related injury). 34 The remainder were taken from a tertiary hospital centre. This study was of low quality, comparing scores with retrospectively examined urine toxicology only, and therefore identifying only illicit or non-prescribed drugs. Subjects were divided into high risk (score8) or low risk (score <8). High risk subjects were younger (P<0.05), gave more urine screens (P<0.01) and had more abnormal results (P<0.05) than those in the low risk group. The SOAPP-R was cross-validated in another prospective study of acceptable quality. 36 This study used a sample of 302 Systematic review Systematic review Systematic review Continued patients, again recruited from pain management centres. The same methods were used as before to assess pain, problematic use and aberrant drug related behaviours, and 73% were followed up at five months when PDUQ, BPI and urine toxicology were undertaken. Sensitivities and specificities were calculated using ROC (receiver operating characteristic) curve analysis, giving an AUC (area under the curve) of 0.74 (95% CI 0.670 -0.810; P<0.001). A cut off score of 18, as used in the initial validation study, gave a sensitivity of 0.79 and specificity of 0.52. Another study further validated the SOAPP-R in 1487 primary care patients, but was of low quality. 37 The size of the study, and the number of clinicians involved, presented particular difficulties, with level of risk sometimes being reduced, and the protocol being poorly adhered to. Urine drug screens were qualitative, and not confirmed by laboratory testing. The ORT (opioid risk tool) was developed 38 using items developed from a literature review and the authors' own experience, and included personal and family history of prescription and illicit drug use and alcohol use. In addition, childhood sexual abuse and selected psychiatric disorders were incorporated, along with age and gender. It was further tested 39 in a retrospective review of prospectively collected data, comparing toxicology results and clinician assessment of aberrant drug related behaviours from patient case notes. Neither clinician nor patient completed tools were found to predict presence of aberrant drug related behaviours. The most recent tools identified were the BRI (brief risk interview) and the BRQ (brief risk questionnaire). The BRI was developed 40 and further validated on another sample referred to a pain clinic using similar methods, and follow up time of six months. 41 It was developed by the first author of both papers from personal experience of using a diagnostic interview, based on an unexplained "introspective process", in combination with review of reports regarding patient risk and discharge. The BRQ was developed from the BRI, to create a self-report tool that would reflect the content of the BRI 42 and included 
Tools measuring current aberrant drug related behaviours or current prescription opioid misuse
Three tools were identified and were reported by five studies, [45] [46] [47] [48] [49] summarised in Table 3 .
To identify the factors contributing to the risk of prescription opioid abuse among patients with chronic, non-malignant pain, 107 consecutive pain clinic patients known to have problems 
Cross-sectional
Recruited from community substance abuse treatment programs, regional jails, pain clinics & private internal medicine practices with abuse were compared with 103 in a control group. 50 This resulted in an un-named tool that was later subject to prospective validation. 45 Three items were identified with odds ratios of more than 100, hence thought to have value in identifying misuse. The authors proposed a simplified tool based on these three items (extreme requirements for opioids, lying to acquire opioids, and "doctor shopping"). The current opioid misuse measure (COMM) was developed in a study of acceptable quality, and was initially validated in a sample of 227 pain management centre patients. 46 This tool was designed to be used for regular monitoring, and screened for misuse of prescribed opioids over the past 30 days. Like the SOAPP, which was developed by the same team, it was based on concept mapping, with input from both pain and addiction specialists and primary care health professionals. It was reduced down from an original 579 items to six clusters, each with between one and five layers. A 40-item alpha version of the COMM was then derived, which was later reduced down to 17 items. The COMM was then validated against a number of other measures shown in Table 4 , notably the aberrant drug behaviour index (ADBI) (calculated from PDUQ, POTQ and toxicology), which was also used in the studies validating the SOAPP. It showed good test-retest reliability (ICC 0.86, 95% CIs 0.77-0.92), and internal reliability (coefficient alpha 0.86). ROC curve analyses were used to evaluate cut-off scores, 9 giving a sensitivity of 0.77 and specificity of 0.68. 86 subjects were reassessed and data reanalysed after three months, and the AUC, using COMM vs ADBI, was 0.92 (95% CIs 0.86-0.98), with a sensitivity of 0.94 and specificity of 0.73. Positive and negative predictive values were also calculated, and were 0.66 and 0.95 respectively, with positive and negative likelihood ratios of 3.48 and 0.08. The COMM was subsequently further validated in two studies, both of acceptable quality. The first study was carried out on a larger sample of 226 subjects recruited from five separate pain management centres. 47 The authors used the 17-item version of the COMM, and similar comparison measures as in the initial derivation study. This study showed similar internal consistency (coefficient alpha 0.83), and ROC analyses gave an AUC of 0.79 (SE 0.031; 95% CI: 0.73 -0.85; P<0.001), with a sensitivity of 0.712 and specificity of 0.713 at the previous cut-off of 9. The other study tested the COMM on a different population, this time of 238 subjects with chronic pain recruited from primary care. 48 This study used the composite international diagnostic interview to make DSM-IV diagnoses, for both prescription drug use 51 All subjects in this study had high rates of posttraumatic stress disorder (48% for those with PDD and 35% for those without), and a majority were in receipt of disability payments (59% for those with PDD and 50% for those without). This may in part reflect the fact that they were recruited from "safety-net" practices, and likely to be disadvantaged with no or minimal insurance. In this population, a cut-off of 13 appeared to be optimal, with sensitivity and specificity both 0.77, positive and negative predictive values of 0.30 and 0.96, and positive and negative likelihood ratios of 3.31 and 0.30. The final study in this group tested the POMI (prescription opioid misuse index). 49 The questions pertained largely to use of pain medication, including increased and more frequent use, more frequent requests, experience of intoxication, use for reasons other than analgesia, and using more than one doctor. Subjects were selected from a larger study investigating oxycontin (modified release oxycodone) dependence.
52
Tools screening for and predicting both current and future aberrant drug related behaviours or prescription opioid misuse
Two tools were identified and reported by four studies [53] [54] [55] [56] as shown in Table 4 .
The PDUQ (prescription drug use questionnaire) was developed based on a literature review and on review and evaluation of patient records. 53 This tool enquired about personal and family history of pain, personal and past history of substance use, mental health, and family and social aspects. Three items were identified that were particularly useful in identifying those with addiction, distinguishing 92.9% of this group (patient belief that they are dependent, increasing opioid medication, and preferring to take medication by a specific route). The PDUQ was later adapted to create a self-report tool, the PDUQp. 54 The OCC (opioid compliance checklist) with versions of this tool have been reported, using different numbers of items. 55 They have different utility depending on time available for assessment and the clinical population. 56 
Studies comparing different tools
Three studies [57] [58] [59] were found which compared different tools, as shown in Table 5 . The DIRE (diagnosis intractability risk and efficacy) score, included here, was excluded from this review as it was retrospective.
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Tools used to monitor/document aberrant drug related behaviours or prescription opioid misuse
Two further papers were identified 61 62 for this purpose, both clinician administered, and are summarised in Table 6 . The The other tool was the ABC (addiction behaviours checklist) and it remained unclear whether it would be best used for regular monitoring or screening purposes. 62 
Systematic reviews
Three systematic reviews were identified. The first included both screening tools and studies that examined predictors of misuse in clinical practice. 17 The second identified studies that both predicted and identified aberrant drug related behaviours before and during opioid prescribing. 18 The final reviewed instruments assessing opioid misuse, and also safety and efficacy in chronic pain. 20 The tools identified in these reviews are listed in Table 1 , and include a number of additional tools that were excluded from this review as the relevant studies did not fit our inclusion criteria: the SISAP (screening instrument for substance abuse potential) 63 ; an unnamed six-item instrument 50 that was further developed into an unnamed four-item instrument 45 ; psychiatric items from the PDUQ 64 ; the mPMQ 65 ;
and the PODS (prescribed opioids difficulties scale). 66 All the systematic reviews were of acceptable or higher quality. The data extracted and conclusions drawn were assessed as being reliable.
Discussion
This review identified a number of instruments, all of which were developed and validated in populations with chronic pain and prescribed opioids in the US. Two studies have undergone validation in other languages. 58 43 There have been no studies validating English language tools in European patient populations. This likely reflects the greater prominence that prescription opioid abuse has achieved in North America. The need to assess risk before and during prescribed opioid therapy is important given the rising number of deaths associated with these medications. 67 In order that opioids and non-opioid medications be preserved as part of a clinician's treatment options, the dangers of their use need to be carefully considered and responded to appropriately. There was variability in how misuse of prescribed opioids was defined. Some applied already codified criteria such as the DSM-IV criteria for substance dependence or explicit reference to Portenoy's criteria. 44 Where study authors described a nonstandardised definition, this included common recognisable features such as inappropriate requests for prescription refills, unauthorised dose escalation and seeking care from multiple providers. Some authors also used laboratory testing for use of opioids that had not been prescribed. Whilst the overlap in definitions is clear, the heterogeneity of the final definition makes comparison of results challenging and is a limitation inherent in this review. Clearly this is an area where consensus amongst researchers and clinicians would be of significant value. Abuse of other classes of prescribed analgesic medication is increasingly recognised, with a particular emphasis on gabapentinoids, 22 and this may be a particular risk in patients who misuse other substances, or who are prescribed opioid substitution therapy. [68] [69] [70] Amitriptyline and some other tricyclic antidepressants are also liable to misuse in some patient groups. 71 This is of relevance as these drugs are considered amongst first line options for pharmacological treatment of neuropathic pain. 72 Gabapentinoids are being identified in drug related death reports in the UK, 67 with high levels of problem use in prisons. 73 The most recently published data on drug-related deaths in Scotland reported the presence of gabapentin in 17% of postmortem samples and concluded that it was implicated in the death of 11% of cases. 67 Although gabapentin is not currently scheduled as a controlled drug, the Advisory Council on the Misuse of Drugs has recommended that this should change, and that appropriate risk assessment should be carried out before prescribing. 74 It is disappointing that no tools have been identified to assist in risk assessment in this area, and does highlight an area of unmet need. 
yr
Most of the tools identified were derived from reviews of the literature, and choice of tool may depend on the population being screened, and resources available. Of the tools that claim to predict prescription opioid misuse, the pain medication questionnaire (PMQ) 28 stands out for being evaluated in several studies of acceptable quality. It is relatively long, with 26 items, but quick and easy to complete, and has been validated against multiple outcome measures. It appears to be a useful tool, dividing subjects into low and high-risk groups.
The SOAPP (and SOAPP-R) is another potentially useful tool, developed and validated 33 35 36 using a rigorous process, providing a strong attempt to counter some of the difficulties alluded to regarding concurrent validity. The other studies that attempted further validation had methodological problems. 34 37 Neither the opioid risk tool (ORT), 38 the brief risk interview (BRI) 40 or brief risk questionnaire (BRQ) 42 could be recommended on the basis of the studies reviewed. Development of the ORT showed methodological difficulties, with lack of evidence of blinding. Both the ORT and the SOAPP-R were used in the studies aiming to develop and validate the BRI and BRQ, but these all showed methodological flaws, with concerns about blinding and lack of confidence intervals. The high performance of the BRI and BRQ compared with the other tools could not, therefore, be supported from these studies alone. [40] [41] [42] The current opioid misuse measure (COMM) appeared to perform best amongst tools aiming to screen for current misuse. 46 
47
The opioid compliance checklist (OCC), developed recently, 55 is a promising tool which may offer more functionality for both screening and predicting, being shorter, and having been developed and further validated in good quality studies. 56 Several features are common across the tools identified. There is no single clear factor that identifies opioid misuse, and caution must be exercised, particularly where decisions are being made regarding whether to prescribe. Previous substance misuse appears important, with differing emphasis on personal or family histories, and whether it pertains to misuse of prescribed or illicit substances, or alcohol. A smoking history may be relevant. 34 Another aspect is that of deception, including lying to clinicians, and using drugs belonging to others. How best to elicit this remains a challenge. In some circumstances, patients may be loath to admit to such practices if they fear their prescription will be at risk. It is easier to obtain a history of psychiatric or psychological disorders, or to enquire about patient characteristics, including disability or employment, or legal problems. Increasing drug requirements and craving, or requests for specific drugs or mode of administration may also be more easily obtained.
Strengths of the present review are the wide range of databases searched, our attempt to identify specific tools of clinical utility and the expansion of our evidence search beyond opioids. The lack of literature regarding screening tools for non-opioid medication abuse and our inability to do a meta-analysis because of heterogeneity of studies are the principle weaknesses.
Conclusions
There is moderate quality evidence to support the use of several tools to either predict increased risk of, or aid in identification of, prescription opioid misuse. However, care must be taken if considering using these tools in different populations from that in which they have been developed and validated. Further studies would be improved by working with an agreed definition of prescription opioid misuse. Accurate information about the extent of prescription opioid misuse is needed, with routine use of a validated risk assessment tools potentially assisting with this aim. Given the recent increase in gabapentinoid misuse, development of specific measures to assess this risk will be of importance as no tools are currently available. Ideally, we envisage the development of a tool that predicts and monitors the emergence of aberrant drug-related behaviours in a population of chronic pain patients who are being considered for, or currently receiving, opioid or adjunct pharmacological treatment.
